Bayer and Vividion Therapeutics to present latest research on their advancing oncology portfolio at AACR 2025 annual meeting: Berlin, Germany Wednesday, April 23, 2025, 10:00 Hrs ...

Two international academic journals have found that it is effective to apply classical treatments to patients with advanced ...

The week marked several FDA approvals for drugs and devices, plus data continues to show tarlatamab’s benefit in small cell lung cancer.

Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug conjugate (AD2C) for hepatocellular carcinoma (HCC). The data will ...

Liver cancer, particularly hepatocellular carcinoma (HCC), has become a major health concern in Uganda. The Uganda Cancer ...

The following is a summary of "Epigenetic-modification associated hnRNPA3 acts as a prognostic biomarker and promotes malignant progression of HCC," published in the April 2025 issue of BMC Cancer by ...

Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114. See why I rate ...

LIVER cancer is the fourth most common cancer in Malaysia and also the fourth leading cause of cancer-related deaths.

Researchers sought to test the performance of a deep learning model system using longitudinal magnetic resonance imaging (MRI) in predicting early recurrence in patients with hepatocellular carcinoma.

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in ...